“During the fourth quarter and into 2025, we made significant progress across our pipeline. Both of our oncology programs have been advancing in the clinic and our obesity program is on schedule for first in human dosing later this month. We were encouraged by the data for CRB-701 from our study in Western patients that has demonstrated a promising safety profile and encouraging evidence of efficacy in multiple advanced tumor types. We look forward to generating informative clinical data from all three of our programs in the 2nd half of this year” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Elastic, Monster, Caesars, Catalyst, Corbus: Stock Shake-Up!
- Corbus Pharmaceuticals initiated with an Outperform at William Blair
- Corbus Pharmaceuticals: Promising ADC Advancements with CRB-701 and Market Opportunities Amidst Risks
- Promising Potential of Corbus Pharmaceuticals’ CRB-701 in Oncology: A Strong Buy Rating by Andrew Fein
- Corbus Pharmaceuticals Reports Promising Phase 1 Trial Results